The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Pozdnyakov D.I.

Pyatigorsk Medical and Pharmaceutical Institute — branch of the Volga State Medical University

Chernikov M.V.

Pyatigorsk Medical and Pharmaceutical Institute — branch of the Volga State Medical University

Sarkisyan K.Kh.

Pyatigorsk Medical and Pharmaceutical Institute — branch of the Volga State Medical University

Rybalko I.E.

Pyatigorsk Medical and Pharmaceutical Institute — branch of the Volga State Medical University

Neuroprotective potential of pyrimidine-4-H1-OHa derivatives in experimental cerebral ischemia

Authors:

Pozdnyakov D.I., Chernikov M.V., Sarkisyan K.Kh., Rybalko I.E.

More about the authors

Read: 1825 times


To cite this article:

Pozdnyakov DI, Chernikov MV, Sarkisyan KKh, Rybalko IE. Neuroprotective potential of pyrimidine-4-H1-OHa derivatives in experimental cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(12):63‑68. (In Russ.)
https://doi.org/10.17116/jnevro202112112163

Recommended articles:
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Rege­nerative modu­lators use in the surgical treatment of ante­rior abdo­minal wall hernias. Russian Journal of Evidence-Based Gastroenterology. 2025;(1):63-70
Anesthetic mana­gement of endo­vascular procedures in patients with ischemic stroke. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):20-25
Socio-economic damage caused by elevated low-density lipo­protein cholesterol levels. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):88-98

References:

  1. Rabinstein AA. Update on Treatment of Acute Ischemic Stroke. Continuum (Minneap Minn). 2020;26(2):268-286.  https://doi.org/10.1212/CON.0000000000000840
  2. Angeloni C, Vauzour D. Natural Products and Neuroprotection. Int J Mol Sci. 2019;20(22):5570. https://doi.org/10.3390/ijms20225570
  3. Stocchetti N, Taccone FS, Citerio G, et al. Neuroprotection in acute brain injury: an up-to-date review. Crit Care. 2015;19(1):186.  https://doi.org/10.1186/s13054-015-0887-8
  4. Bennion DM, Steckelings UM, Sumners C. Neuroprotection via AT2 receptor agonists in ischemic stroke. Clin Sci (Lond). 2018;132(10):1055-1067. https://doi.org/10.1042/CS20171549
  5. Friedrich RP, Pöttler M, Cicha I, et al. Nanomedicine for neuroprotection. Nanomedicine (Lond). 2019;14(2):127-130.  https://doi.org/10.2217/nnm-2018-0401
  6. Chamorro Ángel, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2B/3 trial. Lancet Neurol. 2014;13:453-460.  https://doi.org/10.1016/S1474-4422(14)70054-7
  7. Kim JS, Lee KB, Park J-H, et al. Safety and efficacy of Otaplimastat in patients with acute ischemic stroke requiring tPA (SAFE-tPA): a multicenter, randomized, doubleblind, placebo-controlled phase 2 study. Ann Neurol. 2020;87:233-245.  https://doi.org/10.1002/ana.25644
  8. Lyden P, Pryor KE, Coffey CS, et al. Final results of the RHAPSODY trial: a multicenter, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke. Ann Neurol. 2019;85:125-136.  https://doi.org/10.1002/ana.25383
  9. Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomized controlled trial. The Lancet. 2020;395:878-887.  https://doi.org/10.1016/S0140-6736(20)30258-0
  10. Fargualy AM, Habib NS, Ismail KA, et al. Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives. European Journal of Medicinal Chemistry. 2013;66:276-295.  https://doi.org/10.1016/j.ejmech.2013.05.028
  11. Kumar S, Deep A, Narasimhan B. Pyrimidine derivatives as potential agents acting on central nervous system. Central Nervous System Agents in Medicinal Chemistry. 2015;15(1):5-10.  https://doi.org/10.2174/1871524914666140923130138
  12. Voronkov AV, Pozdnyakov DI, Adjiakhmetova SL, et al. Mitochondrial dysfunction in neurodegenerative and ischemic brain lesions. Experimental and Pharmacological Aspects. K.: Buk; 2020. (In Russ.).
  13. Voronkov AV, Khuri EI, Pozdnyakov DI, Kulbekova EYu, Kobin AA. Antioxidant activity of pyrimidine-4(1H)-it derivatives in traumatic brain injury under experimental conditions. Eksperimental’naya i Klinicheskaya Farmakologiya. 2019;82(1):8-10. (In Russ.). https://doi.org/10.30906/0869-2092-2019-82-1-8-10
  14. Voronkov AV, Pozdnyakov DI. Neuroprotective Effect of L-carnitine. Focus on Changing Mitochondrial Function. Research Results in Pharmacology. 2020;6:29. 
  15. Tamura A, Graham DI, McCulloch J, Teasdale GM. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 1981;1(1):53-60.  https://doi.org/10.1038/jcbfm.1981.6
  16. Spinazzi M, Casarin A, Pertegato V, Salviati L, Angelini C. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nat Protoc. 2012;7(6):1235-1246. https://doi.org/10.1038/nprot.2012.058
  17. Lucas DT, Szweda LI. Declines in mitochondrial respiration during cardiac reperfusion: age-dependent inactivation of alpha-ketoglutarate dehydrogenase. Proc Natl Acad Sci USA. 1999;96(12):6689‐6693. https://doi.org/10.1073/pnas.96.12.6689
  18. Ternette N, Yang M, Laroyia M, et al. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep. 2013;3(3):689-700.  https://doi.org/10.1016/j.celrep.2013.02.013
  19. Shepherd D, Garland PB. The kinetic properties of citrate synthase from rat liver mitochondria. Biochem J. 1969;114(3):597-610.  https://doi.org/10.1042/bj1140597
  20. Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. Published 2020 Jul 14.  https://doi.org/10.1371/journal.pbio.3000410
  21. Yang JL, Mukda S, Chen SD. Diverse roles of mitochondria in ischemic stroke. Redox Biol. 2018;16:263-275.  https://doi.org/10.1016/j.redox.2018.03.002
  22. Khodagholi F, Shaerzadeh F, Montazeri F. Mitochondrial Aconitase in Neurodegenerative Disorders: Role of a Metabolism- related Molecule in Neurodegeneration. Curr Drug Targets. 2018;19(8):973-985.  https://doi.org/10.2174/1389450118666170816124203
  23. Chouchani ET, Pell VR, James AM, et al. A Unifying Mechanism for Mitochondrial Superoxide Production during Ischemia-Reperfusion Injury. Cell Metab. 2016;23(2):254-263.  https://doi.org/10.1016/j.cmet.2015.12.009

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.